How much does retatrutide cost?

Retatrutide cost has no honest dollar answer yet. The drug isn't FDA approved, no pharmacy sells it, and Eli Lilly hasn't set a price (checked 11/06/2026).

Two legal routes exist before approval: a clinical trial or Lilly's expanded access program. In both, Lilly says the drug itself usually costs you nothing.

Here's what each route costs, what Lilly charges for its approved drugs today, and how coverage rules could shape what you pay later.

Can you buy retatrutide at a pharmacy?

No. In a 09/29/2026 release, Lilly calls it an investigational molecule that cannot be legally sold or marketed for human use.

Lilly hasn't asked the FDA for approval yet. Its 07/23/2026 release says Lilly plans to submit a Biologics License Application (BLA) for retatrutide to FDA in Q1 2027. The 09/29/2026 release kept that timing.

A filing is a request, not an approval. The FDA reviews the application after that, and Lilly hasn't named an approval date or a price.

So any retatrutide price you see online isn't a Lilly price. Lilly's third-quarter results on 10/29/2026 went further. Lilly said it calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market.

If you've typed retatrutide where to buy into a search bar, there's a guide built around that question. It covers the legal routes, clinical trials and Lilly's expanded access program, and how to check a seller's lab report.

We don't track prices from sellers outside those routes. Our price rules only allow manufacturer, pharmacy and plan pages.

How much does a retatrutide clinical trial cost?

Usually nothing for the drug or the visits. Lilly's clinical trial information page puts it this way: For most clinical trials, the investigational medicine is provided, and visits are conducted at no cost to the volunteer.

"Most" isn't "all." Lilly adds that Some clinical trials pay or reimburse volunteers. You learn about any costs or payments during informed consent, before you agree to join.

So read the cost section of the consent form. Ask which tests or visits, if any, will be billed to your insurance.

On Medicare? Medicare.gov says Part A and Part B cover some costs in clinical research studies, like office visits and tests. You may pay 20% of the Medicare-approved amount.

Are there retatrutide trials in Ohio?

Few trials are still enrolling. On 11/06/2026, a ClinicalTrials.gov search for retatrutide listed 34 studies. Thirty were completed or no longer recruiting.

One recruiting Lilly study has Ohio sites. It's a Phase 3 trial in adults with fatty liver disease (NCT07165028), testing tirzepatide, retatrutide and a placebo.

Its sites in Akron, Beavercreek and Westlake were recruiting, and a site in Brooklyn, Ohio, wasn't open yet. The study has its own entry rules, including liver test thresholds.

Joining doesn't promise you retatrutide. The trial compares more than one drug with a placebo, so you could get any of them.

What does Lilly's expanded access program cost?

Lilly says the drug is free. Its medical information page states: Lilly provides products at no cost through the expanded access program.

Expanded access, sometimes called compassionate use, lets some patients get an unapproved drug outside a trial. Lilly lists its retatrutide program on ClinicalTrials.gov as available, with the record last updated 08/06/2026.

It's one patient at a time, and the bar is high. Lilly's criteria include:

• Age 18 or older.
• A BMI of 35 or more despite the highest available dose of a weight-management drug.
• Two or more serious or life-threatening obesity-related conditions that are already being treated.
• No way to join a retatrutide trial or a similar one.
• A talk with your doctor about every standard option, including bariatric surgery.

You can't apply yourself. Your treating doctor contacts the Lilly Answers Center at 1-800-545-5979. Lilly asks patients and caregivers to go through their doctor.

A free drug doesn't always mean free care. The FDA's patient page covers the costs of the drug and the care that goes with it. It says these are often not covered by third-party payers such as private insurance or Medicare.

It also warns that costs could be incurred related to IRB review, which may be your responsibility. An IRB is the ethics board that reviews the treatment plan.

What does Lilly charge for Zepbound and Mounjaro today?

This is the closest sourced reference point. It isn't a retatrutide price, and Lilly hasn't said retatrutide will cost the same.

Zepbound and Mounjaro both contain tirzepatide, Lilly's approved weight-loss and diabetes drug. Here's what LillyDirect, Lilly's own pharmacy service, charged self-pay buyers on 11/06/2026:

For Zepbound, Lilly defines a month as 28 days and one KwikPen. Mounjaro costs $499 a month at every strength, and Lilly adds that taxes and fees may apply.

For the full price ladders, see Zepbound without insurance and Mounjaro without insurance.

What did Lilly agree to with the federal government?

On 11/06/2025, the White House announced pricing agreements with Lilly and Novo Nordisk. These are the figures for Lilly's existing drugs, plus what TrumpRx shows today:

One line in that fact sheet points to the future. It says Lilly and Novo Nordisk will guarantee MFN prices on all new medicines that they bring to market. MFN stands for most-favored-nation pricing.

That promise comes with no dollar figure. The fact sheet doesn't name a price for any future drug, so it can't tell you what retatrutide will cost.

Will insurance cover retatrutide after approval?

Nobody knows yet. But today's rules for obesity drugs show where the hurdles are.

Commercial plans. Each job-based or marketplace plan decides whether it covers weight-loss drugs. Many require prior authorization, where your prescriber shows you meet the plan's rules before it pays.

That review is often run by a pharmacy benefit manager, the company that handles a plan's drug benefits. If you're turned down, see how to appeal a GLP-1 denial.

Medicare. Standard Part D leaves out weight-loss uses by law. The Part D statute excludes drug uses that Medicaid may exclude. The Medicaid statute lists Agents when used for anorexia, weight loss, or weight gain.

The current workaround is the Medicare GLP-1 Bridge. Medicare.gov calls it a temporary program that started 07/01/2026, with a $50 copay for a month's supply.

It lists three drugs: Foundayo, Wegovy and the Zepbound KwikPen. Retatrutide isn't one of them. Our Medicare and Wegovy guide covers who qualifies.

Ohio Medicaid. Ohio's Unified Preferred Drug List, effective 10/01/2026, has a GLP-1 category labeled "for Non-Obesity Indications." It lists only Wegovy, with prior authorization, for heart risk or a liver disease called MASH.

The same list sets the rule for anything new: Medications that are new to the market will be non-preferred, PA required, until reviewed by the ODM Pharmacy and Therapeutics (P&T) Committee.

So if retatrutide is approved, it would start out needing prior authorization on Ohio Medicaid. Whether the state would cover it for weight loss would be up to the state.

What will retatrutide cost after approval?

We don't know, and we won't guess. Here's where the facts end.

Facts, checked 11/06/2026:

• Retatrutide isn't FDA approved, and no pharmacy sells it.
• Lilly plans to file for FDA approval in Q1 2027.
• Lilly hasn't published a price.
• Lilly supplies the drug at no cost in most trials and in expanded access.
• Lilly's tirzepatide drugs cost $299 to $699 a month self-pay on LillyDirect, depending on product, strength and refill timing.

Not known: the approval date, the list price, any self-pay price, and which plans will cover it.

When Lilly publishes a price, we'll add it here with its date and log it in the price change log.

How we checked these facts

We read Lilly's releases and LillyDirect pages, TrumpRx, ClinicalTrials.gov, the FDA, Medicare.gov and Ohio's drug list on 11/06/2026. Lilly's investor site blocked our automated checker. So we read its 07/23/2026 and 09/29/2026 releases through the copies Lilly sent out on PR Newswire.